Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) was the target of a significant growth in short interest during the month of July. As of July 31st, there was short interest totalling 49,700 shares, a growth of 21.8% from the July 15th total of 40,800 shares. Currently, 5.7% of the shares of the company are sold short. Based on an average daily trading volume, of 51,500 shares, the days-to-cover ratio is currently 1.0 days.
Hedge Funds Weigh In On Avenue Therapeutics
A hedge fund recently bought a new stake in Avenue Therapeutics stock. Armistice Capital LLC bought a new stake in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI – Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The fund bought 75,000 shares of the company’s stock, valued at approximately $262,000. Armistice Capital LLC owned approximately 7.97% of Avenue Therapeutics as of its most recent filing with the SEC. Institutional investors own 17.34% of the company’s stock.
Avenue Therapeutics Price Performance
Shares of NASDAQ ATXI traded down $0.08 during trading hours on Friday, hitting $2.50. 23,223 shares of the stock were exchanged, compared to its average volume of 66,896. The firm has a market capitalization of $2.35 million, a P/E ratio of -0.32 and a beta of -0.19. Avenue Therapeutics has a one year low of $2.25 and a one year high of $77.25. The company’s 50 day moving average is $3.18 and its 200 day moving average is $6.82.
Avenue Therapeutics Company Profile
Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.
Recommended Stories
- Five stocks we like better than Avenue Therapeutics
- ETF Screener: Uses and Step-by-Step Guide
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What is a Bond Market Holiday? How to Invest and Trade
- MarketBeat Week in Review – 8/12 – 8/16
- Insider Trading – What You Need to Know
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.